Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Elisa H Ignatius"'
Autor:
Elisa H. Ignatius, Binayak Rimal, Chandra M. Panthi, Daniel C. Belz, Christopher K. Lippincott, Daniel H. Deck, Alisa W. Serio, Gyanu Lamichhane
Publikováno v:
mSphere, Vol 9, Iss 7 (2024)
ABSTRACT Treatment outcomes for Mycobacteroides abscessus (Mab, also known as Mycobacterium abscessus) disease are still unsatisfactory, mainly due to issues with drug toxicity, tolerability, and efficacy. Treating Mab disease is challenging due to i
Externí odkaz:
https://doaj.org/article/7ccb62dd0f5245f68304d89d92fc27f0
Autor:
Binayak Rimal, Danielle A. Nicklas, Chandra M. Panthi, Christopher K. Lippincott, Daniel C. Belz, Elisa H. Ignatius, Daniel H. Deck, Alisa W. Serio, Gyanu Lamichhane
Publikováno v:
mSphere, Vol 8, Iss 2 (2023)
ABSTRACT Mycobacteroides abscessus is an opportunistic pathogen in people with structural lung conditions such as bronchiectasis, chronic obstructive pulmonary disease, and cystic fibrosis. Pulmonary M. abscessus infection causes progressive symptoma
Externí odkaz:
https://doaj.org/article/69dd87c747fd41cdb82da060a9dfed37
Autor:
Kamunkhwala Gausi, Maxwell Chirehwa, Elisa H Ignatius, Richard Court, Xin Sun, Laura Moran, Richard Hafner, Lubbe Wiesner, Susan L Rosenkranz, Veronique de Jager, Nihal de Vries, Joseph Harding, Tawanda Gumbo, Susan Swindells, Andreas Diacon, Kelly E Dooley, Helen McIlleron, Paolo Denti
Publikováno v:
J Antimicrob Chemother
Background The WHO-endorsed shorter-course regimen for MDR-TB includes high-dose isoniazid. The pharmacokinetics of high-dose isoniazid within MDR-TB regimens has not been well described. Objectives To characterize isoniazid pharmacokinetics at 5–1
Autor:
Laura Moran, Elisa H. Ignatius, Susan Swindells, Paolo Denti, Richard Hafner, Florian von Groote-Bidlingmaier, Eric L. Nuermberger, Naadira Vanker, Soyeon Kim, Andreas H. Diacon, Kathleen Donahue, Kelly E. Dooley, Susan L. Rosenkranz, Kamunkhwala Gausi, Xin Sun, Lubbe Wiesner
Publikováno v:
American Journal of Respiratory and Critical Care Medicine. 204:1327-1335
Rationale: There is accumulating evidence that higher-than-standard doses of isoniazid are effective against low-to-intermediate-level isoniazid-resistant strains of Mycobacterium tuberculosis, but...
Autor:
Kelly E, Dooley, Bronwyn, Hendricks, Nikhil, Gupte, Grace, Barnes, Kim, Narunsky, Colleen, Whitelaw, Tanya, Smit, Elisa H, Ignatius, Adine, Friedman, Susan E, Dorman, Rodney, Dawson
Publikováno v:
American journal of respiratory and critical care medicine.
Pretomanid is a new nitroimidazole with proven treatment-shortening efficacy in drug-resistant tuberculosis. Pretomanid-rifamycin-pyrazinamide combinations are potent in mice but have not been tested clinically. Rifampicin, but not rifabutin, reduces
Autor:
Rebekah M Dedrick, Krista G Freeman, Jan A Nguyen, Asli Bahadirli-Talbott, Mitchell E Cardin, Madison Cristinziano, Bailey E Smith, Soowan Jeong, Elisa H Ignatius, Cheng Ting Lin, Keira A Cohen, Graham F Hatfull
Publikováno v:
Open Forum Infectious Diseases. 9
An elderly man with refractory Mycobacterium abscessus lung disease previously developed anti-phage neutralizing antibodies while receiving intravenous phage therapy. Subsequent phage nebulization resulted in transient weight gain, decreased C-reacti
Autor:
Susan Swindells, Elisa H. Ignatius
Publikováno v:
Curr HIV/AIDS Rep
PURPOSE OF REVIEW: Despite broad uptake of antiretroviral therapy (ART), tuberculosis (TB) incidence and mortality among people with HIV remain unacceptably high. Short-course regimens for TB, incorporating both novel and established drugs, offer the
Autor:
Kelly E. Dooley, Sachiko Miyahara, Florian von Groote-Bidlingmaier, Xin Sun, Richard Hafner, Susan L. Rosenkranz, Elisa H. Ignatius, Eric L. Nuermberger, Laura Moran, Kathleen Donahue, Susan Swindells, Naadira Vanker, Andreas H. Diacon, Rachel Issa, Christopher Lane, Mark Lojacono, Rachel Mahachi, William Murtaugh, Lynette Purdue, Akbar Shahkolahi, Ronald Ssenyonga
Publikováno v:
Am J Respir Crit Care Med
Rationale: High-dose isoniazid is recommended in short-course regimens for multidrug-resistant tuberculosis (TB). The optimal dose of isoniazid and its individual contribution to efficacy against T...
Autor:
Kelly E. Dooley, Elisa H. Ignatius
Publikováno v:
Advances in Host-Directed Therapies Against Tuberculosis ISBN: 9783030569044
The pharmacokinetics (PK) of a drug is commonly explained as ‘what the body does to the drug’ and is typically described in terms of drug disposition—that is: absorption, distribution, metabolism, and excretion (ADME) of the drug. Pharmacologis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::94f11031478f4a088b091b3d0adf623c
https://doi.org/10.1007/978-3-030-56905-1_22
https://doi.org/10.1007/978-3-030-56905-1_22
Autor:
Michael T. Melia, Tania Jain, Natasha Chida, Zishan K. Siddiqui, Robin K. Avery, Matthew L Robinson, Kunbo Wang, Brian T. Garibaldi, Brent G. Petty, Andrew H. Karaba, Paul W Blair, Paul G. Auwaerter, Yanxun Xu, Elisa H. Ignatius
Publikováno v:
Open Forum Infectious Diseases
Background There is currently no single treatment that mitigates all harms caused by severe acute respiratory syndrome coronavirus 2 infection. Tocilizumab, an interleukin-6 antagonist, may have a role as an adjunctive immune-modulating therapy. Meth